Global container shipping volume to fall 1% on Trump trade policies: Drewry
Maritime consultancy Drewry said on Thursday it expects global container port volume to fall 1 per cent as a direct result of US trade policies.
That would be the third drop in global container shipping demand since London-based Drewry began collecting that data in 1979. Container volume fell 8.4 per cent during the global financial crisis in 2009 and 0.9 per cent in 2020 when the Covid pandemic was declared.
The Trump administration's current policy includes blanket tariffs of 10 per cent on goods from most countries and 145 per cent import duties products from China. China and other countries have hit back with tariffs on US goods.
"Assuming that 2/3 of current tariffs remain in place, US imports from China could fall by 40 per cent," the consultancy said in a slide presentation.
China dominates US imports of consumer goods, industrial products and furniture.
Relocation of Chinese production to countries facing much lower tariffs could offset some of the decline in shipping demand. To that end, US imports from other countries could increase as much as 15 per cent, Drewry said.
When the US escalated tariffs on China earlier this month, Berkshire Hathaway-owned RC Willey Home Furnishings hit pause on all orders from factories there, including some that were ready to be loaded on an outbound ship, said Jeff Child, president of the retailer that has stores in Utah, Nevada, Idaho and California.
At the same time, the company restarted orders from Vietnam. It stopped those orders when the Trump administration targeted that nation with tariffs of 46 per cent. RC Willey resumed orders when Vietnam tariffs were temporarily lowered to 10 per cent for 90 days.
While the tariff turmoil is a headache for retailers, it also is souring shopper sentiment, Child said.
"The biggest killer of consumer confidence is uncertainty and that's where we're at right now."
Economists warn that President Donald Trump's trade policies raise the risk for a recession in the United States, the world's largest economy. A US downturn could quickly spread to other nations around the world.
Worldwide economic output will slow in the months ahead as Trump's steep tariffs on virtually all trading partners begin to bite, the International Monetary Fund said earlier this week.
German container carrier Hapag-Lloyd said on Wednesday that customers have canceled 30 per cent of shipments to the United States from China, spooked by the trade conflict between the world's two largest economies.
The National Retail Federation, whose members include Walmart and Target, forecast earlier this month that US containerized import cargo volume would drop at least 20 per cent year over year in the second half of 2025 as companies that source from China hit pause on orders.
Many containers from China land at the busiest US port in Los Angeles. Its executive director warned that its import volumes could start falling as early as May.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


India Today
an hour ago
- India Today
5 years since Galwan, how India has fortified border with reforms and roads
Five years ago, on June 15, 2020, India lost 20 soldiers in the Galwan Valley clash with China in Eastern Ladakh - an event that not only redefined India-China ties but also triggered a series of reforms in India's defence posture and strategic planning along the Line of Actual Control (LAC).The Galwan clash, which saw Indian troops retaliate without firearms under existing protocols, also caused significant casualties on the Chinese side and marked a complete breakdown in trust between the two the years since, India has significantly restructured its military preparedness, reinforced border infrastructure, and intensified diplomatic engagements. The Indian armed forces enhanced their presence across the LAC, especially in Eastern Ladakh, with rapid deployment of troops and high-altitude warfare equipment. Emergency procurement provisions were invoked to expedite defence acquisitions, including surveillance systems, UAVs, artillery, and medical equipment for extreme terrain. The Galwan incident became a catalyst for infrastructure expansion. The Union Budget for FY 2025-26 allocated Rs 6.81 lakh crore to the Ministry of Defence, a 9.53% increase from the previous year. Of this, Rs 7,146 crore was set aside for the Border Roads Organisation (BRO), which completed 75 projects worth Rs 2,236 crore in 2024 include roads and bridges in strategic regions like Ladakh, Arunachal Pradesh, Sikkim, and Himachal Pradesh. BRO's earlier achievements included the world's highest motorable road at Umling La (19,024 feet) and ongoing development of the Nyoma Airfield and Shinku La last five years have also seen the LAC's digital landscape transformed. Remote villages in Ladakh, including Galwan and Demchok, were connected to 4G networks under a joint initiative by the Indian Army and Bharti Airtel. This step opened up access to telemedicine, digital education, and government schemes, with the potential to improve tourism and local the diplomatic front, over 30 rounds of talks have taken place since 2020. India and China have conducted 21 rounds of Corps Commander-level discussions and multiple Working Mechanism for Consultation & Coordination (WMCC) meetings. Disengagement has occurred at several friction points: Galwan in July 2020, Pangong Tso in February 2021, PP17A (Gogra-Hot Springs) in August 2021, PP15 in September 2022, and most recently, at Demchok and Depsang in October diplomatic meetings also continued. On June 12, 2025, Foreign Secretary Vikram Misri met Chinese Vice Foreign Minister Sun Weidong in Delhi to discuss bilateral ties, people-centric engagement, and reopening direct air services. Talks included progress on resuming hydrological data sharing and finalising an updated air services agreement. Visa facilitation, media exchanges, and commemorations of 75 years of India-China diplomatic relations were also partial disengagement, India remains cautious. 'Galwan was a turning point,' says Maj Gen Ashok Kumar (Retd), Director General of Centre for Joint Warfare Studies. 'It shattered all trust in Chinese political and military leadership. India's vigilance along the LAC is now permanent.'India's response post-Galwan is widely seen as a comprehensive shift—not only in defence and diplomacy but in redefining the strategic calculus of border management. The clash, now etched in national memory, has ensured that preparedness, infrastructure, and international positioning are not reactive but Watch


Time of India
an hour ago
- Time of India
Startups fire up hiring engine in hunt for senior executives
Senior-level hiring is picking up across Startup Inc after a lull, led by companies including early-stage startups that have raised funding in the last few months. Snabbit , Battery Smart, Nawgati, Better Nutrition, Snitch, Univest, Ekincare, Fleetx and Vetic are among those hiring for leadership positions, said founders and executive search firms . Mature players like Flipkart, PhonePe, Lenskart among others are also in the market for senior professionals, mostly for replacement hiring or to fill critical roles in the run-up to an IPO, said recruiters. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Elegant New Scooters For Seniors In 2024: The Prices May Surprise You Mobility Scooter | Search Ads Learn More Undo ETtech 'The overall uptick is driven by three factors: funding, IPOs and AI-first hiring,' said Anshuman Das, CEO of executive search firm Longhouse Consulting. Live Events While back-to-back geopolitical developments like Trump's tariff storm; the India-Pakistan conflict, and now the Israel-Iran tensions, implies lower visibility on the hiring situation in a medium-term scenario, for now, things are looking up. Discover the stories of your interest Blockchain 5 Stories Cyber-safety 7 Stories Fintech 9 Stories E-comm 9 Stories ML 8 Stories Edtech 6 Stories 'There are a lot more conversations happening… mandates for us are likely to go up by 30-40% over the last quarter,' said Ashish Sanganeria, senior partner at executive search firm Transearch, which has landed several senior leadership mandates in the last month. According to Anuj Roy, managing partner at search firm Fidius Advisory, after a slowdown for many months, early-stage startups in India are finally increasing the pace of hiring. 'Many companies that have recently raised funding are focusing on strengthening their leadership teams as they prepare for the next phase of growth.' India's tech startups raised $2.96 billion in Jan-March 2025, a 24% jump over the previous quarter and a 21% rise from the corresponding period last year, according to data from market intelligence platform Tracxn. Scaling up With funding in place, startup founders and HR executives are betting big on leadership talent to steer the road ahead. 'There's a lot of excitement in the sector and leadership hires play a very important role as we look to scale up the business,' says Aayush Agarwal, founder of quick-service app Snabbit, which offers on-demand home services. Snabbit raised $19 million in a Series B funding round led by Lightspeed in May and is planning to hire at least 5-6 senior professionals at the VP/SVP level across operations, technology, growth, product and ancillary functions. For this, it is looking at talent across sectors and actively tapping into investor networks. Battery swapping operator Battery Smart, which raised $29 million in its Series B round in May, has seen senior hiring picking up significantly compared to last year. With the recent fundraise and aggressive expansion plans, the company says it's imperative to have experienced leaders who can scale teams, drive innovation, and build high-reliability systems. 'We are currently hiring for leadership roles across technology, growth, and supply chain. While the startup ecosystem remains a key source of talent, we're also tapping into sectors like manufacturing, FMCG, consulting, and tech services to infuse fresh perspectives and operational depth,' said Nitasha Sharma, associate director, talent acquisition, Battery Smart.


Mint
an hour ago
- Mint
China's Biotech Moment Ignites a 60% Stock Rally That Beats AI
China's biotechnology stocks have shaken off a four-year slump to be among the hottest performers in Asia this year and funds are tipping further gains. The Hang Seng Biotech Index has surged more than 60% since the start of January amid investor enthusiasm over a pair of billion-dollar deals involving foreign firms licensing Chinese drugs. Share gains at two highly anticipated listings of local producers have further burnished the sector's appeal. 'China biotech is no longer just an emerging story — unlike 10 years ago — it is now a disruptive force reshaping global drug innovation,' said Yiqi Liu, senior investment analyst at Exome Asset Management LLC in New York. 'The science is real, the economics are compelling, and the pipeline is starting to deliver.' The surge in China-listed biotech firms is further evidence that the mainland is becoming a center for global innovation. The rally in the sector this year outpaces the 17% gain in China's tech stocks that was driven by the release of DeepSeek's breakthrough artificial-intelligence app in January. A major reason for the share gains were two mega-sized licensing deals. Pfizer Inc. said on May 19 it had agreed to pay a record $1.25 billion to license an experimental cancer drug from China's 3SBio Inc., and also invest $100 million in the firm's shares. Two weeks later, Bristol-Myers Squibb Co. said it would pay Germany's BioNTech SE as much as $11.5 billion to license a cancer drug that BioNTech had itself licensed from China's Biotheus Inc. in 2023. Some of the gains in biotech shares this year have been stratospheric. 3SBio has surged 283%, topping a Bloomberg gauge of global biotech stocks. RemeGen Co., which develops antibody drugs, has climbed more than 270% after saying it was approached by multinational pharmaceutical firms for potential licensing deals. China's growing influence through pharmaceutical mergers and acquisitions and deal-making is also causing investors to take note. In the first quarter alone, the value of such deals involving local players doubled from the year before to $36.9 billion. That amount made up more than half the global total of $67.5 billion. Chinese biotech companies are having 'their own DeepSeek moment,' said Dong Chen, chief Asia strategist at Pictet Wealth Management in Hong Kong. There is more upside from here, he said. Investor interest in biotech — which involves the use living organisms to make medicines and other products — can be seen in the big runup at recent initial public offerings. Shares of Duality Biotherapeutics Inc., which develops cancer treatments, more than doubled on their first day of trading in Hong Kong on April 15. Jiangsu Hengrui Pharmaceuticals Co., the nation's largest drugmaker by market value, saw its stock jump 25% on debut May 23, even after being issued at the top end of the marketed range. Duality has now risen 189% since its IPO, while Jiangsu has gained 31%. Still, some say the rally may be getting stretched. 'Bears, mostly healthcare specialists, plan to take profit at this point, and some investors prefer the healthcare laggers with capability of constant dividend payout and stable revenue growth,' Bank of America Corp. analysts including Ethan Cui in Hong Kong wrote in a research note this month. Some investors also said they viewed the rush of recent licensing deals as a one-off, and they were refusing to grant valuation multiples to the companies, the analysts wrote. While the recent ratcheting up of trade tensions between the US and China has been a negative for many mainland firms, it's also resulted in talent flowing back to China and creating more research-and-development capability, according to Nicholas Chui, a Chinese equity fund manager at Franklin Templeton in Hong Kong. Jefferies is also bullish, saying the increase in US tariffs is unlikely to prove an obstacle to Chinese biotech firms. Many of the Chinese biotech companies already have US partners and are therefore considered as service providers rather than product exporters, said Cui Cui, head of Asia healthcare research at the company in New York. With assistance from Dong Lyu. This article was generated from an automated news agency feed without modifications to text.